LEAVO: a multicentre phase iii double-masked randomised controlled non-inferiority trial comparing the clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for macular oedema (MO) due to central retinal vein occlusion (CRVO)

Philip Hykin, Sobha Sivaprasad, A. Toby Prevost, Joana Vasconcelos, Caroline Murphy, Joanna Kelly, J.E Brazier, Hasan Basarir, Simon Harding, Yit Yang, Usha Chakravarthy, Andrew J Lotery

Research output: Contribution to journalArticlepeer-review

19 Downloads (Pure)
Original languageEnglish
JournalThe Lancet
Publication statusAccepted/In press - 19 May 2016

Cite this